CREATE Medicines, formerly Myeloid Therapeutics, raised $122 million to advance its first in vivo CAR-T candidates targeting autoimmune disease into human trials. The funding round expands the startup’s pipeline while reflecting investor demand for in vivo approaches intended to simplify CAR-T manufacturing and broaden accessibility. CREATE’s rebrand and expanded scope beyond solid tumor work toward autoimmune indications signals a shift toward earlier clinical translation in settings where immune modulation may offer durable benefit. With the company now funded for human studies, near-term milestones will likely center on first-in-human safety, dose escalation, and expansion cohort activity—key steps for validating the in vivo CAR-T platform concept.